Head and neck cancer squamous cell carcinoma trang 1 tải miễn phí từ TAILIEUCHUNG

"Head and neck cancer squamous cell carcinoma" trang 1 - tải miễn phí từ Tailieuchung

Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort

Update of a prognostic survival model in head and neck squamous cell carcinoma patients treated with immune checkpoint inhibitors using an expansion cohort

10 12 1

Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma

Expression of Oct3/4 and Nanog in the head and neck squamous carcinoma cells and its clinical implications for delayed neck metastasis in stage I/II oral tongue squamous cell carcinoma

14 49 1

Cancer cell line microarray as a novel screening method for identification of radioresistance biomarkers in head and neck squamous cell carcinoma

Cancer cell line microarray as a novel screening method for identification of radioresistance biomarkers in head and neck squamous cell carcinoma

11 44 1

Central neck lymph node metastasis in oral squamous cell carcinoma at the floor of mouth

Central neck lymph node metastasis in oral squamous cell carcinoma at the floor of mouth

7 27 1

Natural history of superficial head and neck squamous cell carcinoma under scheduled follow-up endoscopic observation with narrow band imaging: Retrospective cohort study

Natural history of superficial head and neck squamous cell carcinoma under scheduled follow-up endoscopic observation with narrow band imaging: Retrospective cohort study

8 69 1

Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

9 51 1

Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma

Tbx3 represses PTEN and is over-expressed in head and neck squamous cell carcinoma

12 53 1

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

Cetuximab plus platinum-based chemotherapy in head and neck squamous cell carcinoma: A randomized, double-blind safety study comparing cetuximab produced from two manufacturing processes using the EXTREME study regimen

10 48 1

5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-Lalanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells

5-lipoxygenase mediates docosahexaenoyl ethanolamide and N-arachidonoyl-Lalanine-induced reactive oxygen species production and inhibition of proliferation of head and neck squamous cell carcinoma cells

14 57 1

Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt

Salinomycin induces cell death and differentiation in head and neck squamous cell carcinoma stem cells despite activation of epithelial-mesenchymal transition and Akt

14 39 1

Patterns of recurrence after selective postoperative radiation therapy for patients with head and neck squamous cell carcinoma

Patterns of recurrence after selective postoperative radiation therapy for patients with head and neck squamous cell carcinoma

10 49 1

Wilms’ tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck

Wilms’ tumor gene 1 regulates p63 and promotes cell proliferation in squamous cell carcinoma of the head and neck

12 37 1

Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck

Site disparities in apoptotic variants as predictors of risk for second primary malignancy in patients with squamous cell carcinoma of the head and neck

9 40 1

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: A nationwide retrospective cohort study (KCSG HN13–01)

Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: A nationwide retrospective cohort study (KCSG HN13–01)

9 35 1

Bioinformatics analysis of the expression and role of microRNA-221-3p in head and neck squamous cell carcinoma

Bioinformatics analysis of the expression and role of microRNA-221-3p in head and neck squamous cell carcinoma

15 34 1

Transcriptome analysis reveals the prognostic and immune infiltration characteristics of glycolysis and hypoxia in head and neck squamous cell carcinoma

Transcriptome analysis reveals the prognostic and immune infiltration characteristics of glycolysis and hypoxia in head and neck squamous cell carcinoma

19 8 1

Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma

Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma

11 42 1

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial

Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial

10 45 1

A rare case of extremely high counts of circulating tumor cells detected in a patient with an oral squamous cell carcinoma

A rare case of extremely high counts of circulating tumor cells detected in a patient with an oral squamous cell carcinoma

8 52 1

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

15 54 1

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.